Figure 3.
Current functional nanomedicines for different TAMs-focused cancer immunotherapeutic strategies, including (A) blockage of recruitment, (B) depletion of M2 population, (C) reprogramming of TAMs phenotype. Partial images were adapted with permission from 42, copyright 2019 Royal Society of Chemistry; 46 copyright 2020, 47 copyright 2020, 60 copyright 2014, 62 copyright 2021, 64 copyright 2019, 65 copyright 2014, 77 copyright 2019, 78 copyright 2020 Elsevier Ltd.; 41 copyright 2017, 50 copyright 2018, 59 copyright 2020, 61 copyright 2020, 71 copyright 2019, 72 copyright 2018, 74 copyright 2018, 79 copyright 2018, 80 copyright 2017 American Chemical Society; 44 copyright 2019, 66 copyright 2015, 81 copyright 2021, 82 copyright 2019, 83 copyright 2019, 84 copyright 2020, 85 copyright 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim; 51, copyright 2021 Ivyspring International Publisher; 67 copyright 2017, 86 copyright 2019 Springer Nature Limited.